

New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone Nasal Spray	Opioid Antagonist	Opioid Overdose	Launch pending. Approved March 2023.
Ansofaxine	Antidepressant	Major Depressive Disorder	FDA review pending.
Buprenorphine Depot Injection (Brixadi [™])	Opioid Agonist	Treatment of Opioid Addiction	FDA review pending.
Oxycodone (Aximris XR [™])	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Meloxicam/Rizatriptan	NSAID/Serotonin Agonist	Migraine Headache	FDA review pending.
Naloxone Nasal Spray (RiVive [™])	Opioid Antagonist	Opioid Overdose	FDA review pending for OTC formulation.

Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Cariprazine (Vraylar [®])	Antipsychotic	Schizophrenia & Bipolar I Disorder	Generic approved September 2022.
Apixaban (Eliquis [®])	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.

Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Bupropion/Dextromethorphan (Auvelity [™])	Antidepressant	Major Depressive Disorder	October 2022
Nalmefene Injection	Opioid Antagonist	Opioid Overdose	June 2022
Baclofen Granules (Lyvispah [®])	Muscle Relaxant	Muscle Spasticity	June 2022

Report

Monthly New Drug and First Time Generic March 2023



Available in the Last 12 Months

Newly Available Generics

Lurasidone (Latuda®)	Antidepressant	Depression	February 2023
Didofenac Potassium (Cambia®) Solution	NSAID	Migraine Headache Treatment	January 2023
Topiramate (Trokenidi XR®) ER Capsule	Anticonvulsant	Neuropathic Pain	January 2023
Dabigatran (Pradaxa®)	Anticoagulant	Deep Vein Thrombosis	June 2022
Vilazodone (Viibryd®)	Antidepressant	Depression	June 2022
Diclofenac Sodium 2% (Pennsaid®) Solution	Topical NSAID	Pain	May 2022

Discontinuations & Withdrawals

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Hydrocodone ER Capsules (Zohydro® ER)	Opioid Antagonist	Pain	Manufacturer has stopped distribution and FDA has rescinded approval effective February 2022.